2 results
Approved WMOPending
Primary objective:- To determine the safety and optimal dose of three doses of a novel therapeutic vaccine (ISA104) consisting of 12 synthetic long peptides, as well as an adjuvant agent (AmplivantTM), in patients with chronic hepatitis B (cHBV),…
Approved WMOWill not start
Primary objectiveTo evaluate the efficacy of BMS-986263 compared with placebo to improve liver fibrosis in participants with compensated cirrhosis due to NASHSecondary objectives1. To further assess the efficacy of BMS-986263 compared with placebo…